Quotes 5-day view Delayed Nasdaq
37 992 Volume
Net income 2020
Net income 2021
P/E ratio 2020
P/E ratio 2021
Capi. / Sales2020
Capi. / Sales2021
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system...
Surperformance© ratings of Replimune Group, Inc.
Trading Rating :
Investor Rating : -
Latest news on REPLIMUNE GROUP, INC.
10/15 REPLIMUNE GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-..
10/15 Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Sq..
10/02 REPLIMUNE : Announces Presentation at the 2019 Society for Immunotherapy of Canc..
10/01 Replimune to Present at Chardan's 3rd Annual Genetic Medicines Conference
09/10 REPLIMUNE GROUP, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
08/14 REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
08/14 REPLIMUNE : 2015 Enterprise Management Incentive Share Option Plan
08/14 REPLIMUNE : Reports First Fiscal Quarter Financial Results and Provides Corporat..
08/08 REPLIMUNE GROUP, INC. : Entry into a Material Definitive Agreement, Creation of ..
08/06 REPLIMUNE : to Present at 2019 Wedbush PacGrow Healthcare Conference
06/28 REPLIMUNE : Management's discussion and analysis of financial condition and resu..
06/28 REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
06/28 Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and P..
06/13 REPLIMUNE GROUP, INC. : Entry into a Material Definitive Agreement, Financial St..
06/03 REPLIMUNE : Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2..
News in other languages on REPLIMUNE GROUP, INC.
- No features available -
Sector news : Biotechnology & Medical Research - NEC
Chart REPLIMUNE GROUP, INC.
Technical analysis trends REPLIMUNE GROUP, INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Number of Analysts
Average target price
Last Close Price
Spread / Highest target
Spread / Average Target
Spread / Lowest Target